Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
MOORESTOWN, N.J., Oct. 11, 2016 -- Tabula Rasa HealthCare (NASDAQ:TRHC) Chairman and CEO Calvin H. Knowlton, PhD, today announced changes to TRHC’s corporate C-suite.
Current General Counsel and Chief Strategy Officer, Brian J. Litten, Esq., is being promoted to lead the new Office of Strategy Development (OSD). In this expanded role, Litten will retain his title of Chief Strategy Officer. He will oversee all product development, sales and implementation focused on new markets outside of the company’s PACE (Programs of All-Inclusive Care for the Elderly) market. The OSD team will be developed over the next six months.
The OSD was created to formalize the expansion of TRHC’s Medication Risk Mitigation™ platform. According to CEO Knowlton, the OSD will target markets for TRHC’s Medication Risk Mitigation (MRM) platform, which are separate from its ongoing PACE market. “We have asked Brian Litten, Esq., formerly a health insurance company executive, to lead this new initiative under his continued title as Chief Strategy Officer,” Knowlton reported.
“We also are pleased to announce Kevin J. Dill, Esq., will serve as TRHC’s General Counsel and Chief Compliance Officer,” Knowlton said. “Kevin brings valuable public-company experience in the areas of risk assessment, compliance oversight, and efficiency of healthcare operations. I have asked Brian and Kevin to collaborate over the next few months to transition TRHC’s legal work to the Office of General Counsel. Until the completion of this transition, Brian will continue to serve as our General Counsel, while building the new Office of Strategic Development.”
Dill comes to TRHC from Olympus Corporations of the Americas, where he served as Chief Compliance Officer handling implementation of comprehensive compliance procedures and assessments across Americas for the $2.5B medical device and consumer products company with a field force of over 1,000 sales representatives and distributor network. He is recognized for leading healthcare businesses in design and execution of strategies that ensure operations are in full compliance with laws and regulations, and for providing guidance to company executives and Board of Directors on compliance risks and remediation strategies.
Dill received a Juris Doctor (JD) degree from Temple University, Beasley School of Law, Philadelphia, PA; Doctor of Ministry (DMin), Princeton Theological Seminary; and Bachelor of Arts (BA), Gettysburg College, Gettysburg, PA.
Dill will begin his tenure at TRHC starting October 17, 2016.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.TRHC.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]
